Cargando…

Effect of Oral Propranolol on Periocular Infantile Capillary Hemangioma: Outcomes Based on Extent of Involvement

PURPOSE: To evaluate the efficacy of oral propranolol in the treatment of periocular infantile capillary hemangioma (CHI) based on the involvement of embryological facial placodes and their extent of anatomical involvement. METHODS: Retrospective study of 27 patients. RESULTS: The mean age at the pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bejjanki, Kavya M., Akhtar, Kahkashan, Gupta, Arushi P., Kaliki, Swathi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270022/
https://www.ncbi.nlm.nih.gov/pubmed/34321816
http://dx.doi.org/10.4103/meajo.MEAJO_228_19
_version_ 1783720711352745984
author Bejjanki, Kavya M.
Akhtar, Kahkashan
Gupta, Arushi P.
Kaliki, Swathi
author_facet Bejjanki, Kavya M.
Akhtar, Kahkashan
Gupta, Arushi P.
Kaliki, Swathi
author_sort Bejjanki, Kavya M.
collection PubMed
description PURPOSE: To evaluate the efficacy of oral propranolol in the treatment of periocular infantile capillary hemangioma (CHI) based on the involvement of embryological facial placodes and their extent of anatomical involvement. METHODS: Retrospective study of 27 patients. RESULTS: The mean age at the presentation of periocular CHI was 4 months (median, 3 months; range, <1–14 months). There were 11 (41%) males and 16 (59%) females. Based on embryological facial placodes, the involvement was focal in 16 (59%) cases and segmental in 11 (41%) cases. Based on the anatomical distribution, the lesions were preseptal in 4 (15%), postseptal in 13 (48%), and combined in 10 (37%) cases. The duration of use of oral propranolol was 10 months (median, 10 months; range, 4–16 months). Overall, the mean % resolution of periocular CHI was 78% (median, 90%; range, 20%–100%). The mean percentage resolution of focal lesions was 69% (median, 83%; range, 20%–100%), and segmental lesions were 92% (median, 95%; range, 70%–100%). The mean percentage resolution of preseptal component of lesions was 94% (median, 95%; range, 80%–100%) and postseptal component was 74% (median, 85%; range, 20%–100%) over a mean follow-up period of 16 months (median, 15 months; range, 4–37 months). Four (15%) patients exhibited flare-up of lesion after tapering oral propranolol. CONCLUSION: Oral propranolol is effective in the treatment of periocular CHI. Segmental and preseptal lesions respond better to the treatment compared to focal and postseptal lesions.
format Online
Article
Text
id pubmed-8270022
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-82700222021-07-27 Effect of Oral Propranolol on Periocular Infantile Capillary Hemangioma: Outcomes Based on Extent of Involvement Bejjanki, Kavya M. Akhtar, Kahkashan Gupta, Arushi P. Kaliki, Swathi Middle East Afr J Ophthalmol Original Article PURPOSE: To evaluate the efficacy of oral propranolol in the treatment of periocular infantile capillary hemangioma (CHI) based on the involvement of embryological facial placodes and their extent of anatomical involvement. METHODS: Retrospective study of 27 patients. RESULTS: The mean age at the presentation of periocular CHI was 4 months (median, 3 months; range, <1–14 months). There were 11 (41%) males and 16 (59%) females. Based on embryological facial placodes, the involvement was focal in 16 (59%) cases and segmental in 11 (41%) cases. Based on the anatomical distribution, the lesions were preseptal in 4 (15%), postseptal in 13 (48%), and combined in 10 (37%) cases. The duration of use of oral propranolol was 10 months (median, 10 months; range, 4–16 months). Overall, the mean % resolution of periocular CHI was 78% (median, 90%; range, 20%–100%). The mean percentage resolution of focal lesions was 69% (median, 83%; range, 20%–100%), and segmental lesions were 92% (median, 95%; range, 70%–100%). The mean percentage resolution of preseptal component of lesions was 94% (median, 95%; range, 80%–100%) and postseptal component was 74% (median, 85%; range, 20%–100%) over a mean follow-up period of 16 months (median, 15 months; range, 4–37 months). Four (15%) patients exhibited flare-up of lesion after tapering oral propranolol. CONCLUSION: Oral propranolol is effective in the treatment of periocular CHI. Segmental and preseptal lesions respond better to the treatment compared to focal and postseptal lesions. Wolters Kluwer - Medknow 2021-04-30 /pmc/articles/PMC8270022/ /pubmed/34321816 http://dx.doi.org/10.4103/meajo.MEAJO_228_19 Text en Copyright: © 2021 Middle East African Journal of Ophthalmology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Bejjanki, Kavya M.
Akhtar, Kahkashan
Gupta, Arushi P.
Kaliki, Swathi
Effect of Oral Propranolol on Periocular Infantile Capillary Hemangioma: Outcomes Based on Extent of Involvement
title Effect of Oral Propranolol on Periocular Infantile Capillary Hemangioma: Outcomes Based on Extent of Involvement
title_full Effect of Oral Propranolol on Periocular Infantile Capillary Hemangioma: Outcomes Based on Extent of Involvement
title_fullStr Effect of Oral Propranolol on Periocular Infantile Capillary Hemangioma: Outcomes Based on Extent of Involvement
title_full_unstemmed Effect of Oral Propranolol on Periocular Infantile Capillary Hemangioma: Outcomes Based on Extent of Involvement
title_short Effect of Oral Propranolol on Periocular Infantile Capillary Hemangioma: Outcomes Based on Extent of Involvement
title_sort effect of oral propranolol on periocular infantile capillary hemangioma: outcomes based on extent of involvement
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270022/
https://www.ncbi.nlm.nih.gov/pubmed/34321816
http://dx.doi.org/10.4103/meajo.MEAJO_228_19
work_keys_str_mv AT bejjankikavyam effectoforalpropranololonperiocularinfantilecapillaryhemangiomaoutcomesbasedonextentofinvolvement
AT akhtarkahkashan effectoforalpropranololonperiocularinfantilecapillaryhemangiomaoutcomesbasedonextentofinvolvement
AT guptaaruship effectoforalpropranololonperiocularinfantilecapillaryhemangiomaoutcomesbasedonextentofinvolvement
AT kalikiswathi effectoforalpropranololonperiocularinfantilecapillaryhemangiomaoutcomesbasedonextentofinvolvement